Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide safety and efficacy in HIV patients with hepatic insufficiency
ChiCTR2200066652Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Nanjing
- Start
- Feb 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of albuvirtide in human immunodeficiency virus infection (HIV), sponsored by The Second Hospital of Nanjing. Primary endpoint: Transaminase elevation events. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
albuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2200066652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066652.